Comparing the current results to its competitors, Cryoport Inc reported Revenue increase in the 1 quarter 2026 by 16.47 % year on year. The sales growth was above Cryoport Inc 's competitors' average revenue growth of 6.46 %, achieved in the same quarter.
Cryoport Inc 's Comment on Competition and Industry Peers
Our products and services are sold into a rapidly growing segment of the logistics
industry focused on the temperature sensitive packaging and shipping of biological
materials. Expenditures for “value added” packaging for frozen transport
have been increasing for the past several years and, due in part to continued
globalization, are expected to continue to increase even more in the future as
more domestic and international biotechnology firms introduce pharmaceutical products
that require continuous refrigeration at cryogenic temperatures. We believe this
will require a greater dependence on passively controlled temperature transport
systems (i.e., systems having no external power source). In addition, we expect
that industry standards and regulations will be introduced globally, requiring
more comprehensive tracking and validation of shipping temperatures.
We believe that growth in the following markets has resulted in the need for increased
reliability, efficiencies and greater flexibility in the temperature sensitive
segment of the logistics market:
· cell-based therapies
· gene and stem cell biotechnology
· cell lines
· vaccine production
· commercial drug product distribution
· clinical trials, including transport of tissue culture samples
· diagnostic specimens
· infectious sample materials
· inter/intra-laboratory diagnostic testing
· temperature-sensitive specimens
· biological samples, in general
· environmental sampling
· IVF
· animal husbandry
Many of the biological products in these above markets require transport in a
frozen state as well as the need for shipping containers which have the ability
to maintain a frozen, cryogenic environment (e.g., minus 150° Celsius) for
a period ranging from two to ten days (depending on the distance and mode of shipment).
These products include stem cells, semen, embryo, tissue, tissue cultures, cultures
of viruses and bacteria, enzymes, DNA materials, vaccines and certain pharmaceutical
products.
One of the integral parts of our solutions are our Cryoport Express® Shippers
that are based on a liquid nitrogen dry vapor technology. The following paragraphs
compare our shippers with dry ice and liquid nitrogen shipping methods. Our solutions
integrate the Cryoport Express® Shippers with our CryoportalTM logistics software
platform and our cold chain logistics know-how that are comprehensive and tailored
to client requirements.
Overall company sales advanced by 16.47 % Cryoport Inc outperformed its competitors in this segment and improved market share, to approx. 0.37 %. << More on CYRX Market Share.
*Market share is calculated based on total revenue.
Charles River Laboratories International inc Share Performance
+78.75%
One Year
Charles River Laboratories International inc
Profile
Charles River Laboratories International Inc is a contract research organization (CRO) that provides essential services and support to the pharmaceutical, biotech, and medical device industries. They offer a wide range of research models, drug discovery and development services, safety assessments, and laboratory animal medicine to assist in the preclinical and clinical stages of drug development.
Catalent Incs business model centers around offering comprehensive development and delivery solutions to pharmaceutical, biotechnology, and consumer health companies. By providing a diverse array of services such as drug development, manufacturing, packaging, and supply chain management, they aim to expedite the market entry of innovative and life-saving products for their clients.
Evotec SE is a German drug discovery and development company that operates on a contract research organization (CRO) business model. They offer a comprehensive range of services to pharmaceutical and biotechnology companies, including target identification and validation, hit identification, and lead optimization. Through collaborations and partnerships, Evotec aims to accelerate the discovery and development of new drugs and therapies.
Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.
Sources:
Cryoport inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cryoport inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.